Dr. Anthony Fauci warns that new coronavirus cases could skyrocket to 100,000 cases a day. Yahoo Finance’s Anjalee Khemlani weighs in.
ADAM SHAPIRO: Now we turn our attention to COVID-19 and the coronavirus. Anjalee Khemlani is joining us with the latest. And, you know, Anthony Fauci, Dr. Fauci really-- I don't want to say shocked a lot of people but made a lot of people worried when he testified yesterday, right?
ANJALEE KHEMLANI: That's correct. Yeah, so we heard him really talk about a number of things, including what some states are doing and not doing in response and what the overall sort of responses have been and how that has led to this resurgence.
And while the United States did have sort of a daily average about 20,000 cases a day, we're reaching now an average of 40,000. So that's doubling in just a couple of months. And the prediction was that now that could be as high as 100,000 cases. So if you want to listen to what he has to say about that, it was very-- it was very concerning for a lot of public-health experts.
ADAM SHAPIRO: Also, there's been news about Pfizer today. Can you tell us about that?
ANJALEE KHEMLANI: That's correct. So Pfizer did release the results of the phase one/two trial for its vaccine candidate. And we have to remember, this is one of those leading candidates in the vaccine race depending on a very new technology in terms of what the market has already experienced, similar to Moderna which is the leading candidate. That mRNA technology is what's being used, and it's a combination-- or a partnership, rather, with Pfizer and BioNTech, which is a German company.
And so what their results showed is that there is a positive response. The vaccine does respond to the virus and can protect at some level against it, but what those levels are exactly and how long they would last, all of that stuff would be sort of filtered out in the next phase of the trials.
Meanwhile, we know that they used participants between 18 and 55-year-old group of 45 participants, and that's where they're getting this results from. They also tested three different dosages, and the two lower doses did have a pretty good response. And so that's really helpful because what we're looking at when it comes to these vaccines is lower doses being more effective so that they can produce more as a result. Adam.